These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 16990779)
1. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein. Pinilla-Ibarz J; May RJ; Korontsvit T; Gomez M; Kappel B; Zakhaleva V; Zhang RH; Scheinberg DA Leukemia; 2006 Nov; 20(11):2025-33. PubMed ID: 16990779 [TBL] [Abstract][Full Text] [Related]
2. Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses. Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Roberts W; Scheinberg DA Haematologica; 2005 Oct; 90(10):1324-32. PubMed ID: 16219568 [TBL] [Abstract][Full Text] [Related]
3. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141 [TBL] [Abstract][Full Text] [Related]
4. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes. Kessler JH; Bres-Vloemans SA; van Veelen PA; de Ru A; Huijbers IJ; Camps M; Mulder A; Offringa R; Drijfhout JW; Leeksma OC; Ossendorp F; Melief CJ Leukemia; 2006 Oct; 20(10):1738-50. PubMed ID: 16932347 [TBL] [Abstract][Full Text] [Related]
5. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571 [TBL] [Abstract][Full Text] [Related]
6. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1. Asemissen AM; Keilholz U; Tenzer S; Müller M; Walter S; Stevanovic S; Schild H; Letsch A; Thiel E; Rammensee HG; Scheibenbogen C Clin Cancer Res; 2006 Dec; 12(24):7476-82. PubMed ID: 17189421 [TBL] [Abstract][Full Text] [Related]
7. Enhancement of lytic activity of leukemic cells by CD8+ cytotoxic T lymphocytes generated against a WT1 peptide analogue. Al Qudaihi G; Lehe C; Negash M; Al-Alwan M; Ghebeh H; Mohamed SY; Saleh AJ; Al-Humaidan H; Tbakhi A; Dickinson A; Aljurf M; Dermime S Leuk Lymphoma; 2009 Feb; 50(2):260-9. PubMed ID: 19197722 [TBL] [Abstract][Full Text] [Related]
8. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro]. Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063 [TBL] [Abstract][Full Text] [Related]
9. Synthetic peptides derived from the Wilms' tumor 1 protein sensitize human T lymphocytes to recognize chronic myelogenous leukemia cells. Müller L; Knights A; Pawelec G Hematol J; 2003; 4(1):57-66. PubMed ID: 12692522 [TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes. Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319 [TBL] [Abstract][Full Text] [Related]
11. Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptor. Tamanaka T; Oka Y; Fujiki F; Tsuboi A; Katsuhara A; Nakajima H; Hosen N; Nishida S; Lin YH; Tachino S; Akatsuka Y; Kuzushima K; Oji Y; Kumanogoh A; Sugiyama H Anticancer Res; 2012 Dec; 32(12):5201-9. PubMed ID: 23225417 [TBL] [Abstract][Full Text] [Related]
12. In vitro stimulation with WT1 peptide-loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptide-specific T cells with in vitro and in vivo tumoricidal activity. Doubrovina ES; Doubrovin MM; Lee S; Shieh JH; Heller G; Pamer E; O'Reilly RJ Clin Cancer Res; 2004 Nov; 10(21):7207-19. PubMed ID: 15534094 [TBL] [Abstract][Full Text] [Related]
13. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes. Buzyn A; Ostankovitch M; Zerbib A; Kemula M; Connan F; Varet B; Guillet JG; Choppin J Eur J Immunol; 1997 Aug; 27(8):2066-72. PubMed ID: 9295046 [TBL] [Abstract][Full Text] [Related]
14. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product. Oka Y; Elisseeva OA; Tsuboi A; Ogawa H; Tamaki H; Li H; Oji Y; Kim EH; Soma T; Asada M; Ueda K; Maruya E; Saji H; Kishimoto T; Udaka K; Sugiyama H Immunogenetics; 2000 Feb; 51(2):99-107. PubMed ID: 10663572 [TBL] [Abstract][Full Text] [Related]
15. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Dannull J; Diener PA; Prikler L; Fürstenberger G; Cerny T; Schmid U; Ackermann DK; Groettrup M Cancer Res; 2000 Oct; 60(19):5522-8. PubMed ID: 11034097 [TBL] [Abstract][Full Text] [Related]
16. WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation. Weber G; Karbach J; Kuçi S; Kreyenberg H; Willasch A; Koscielniak E; Tonn T; Klingebiel T; Wels WS; Jäger E; Bader P Leukemia; 2009 Sep; 23(9):1634-42. PubMed ID: 19357702 [TBL] [Abstract][Full Text] [Related]
17. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296 [TBL] [Abstract][Full Text] [Related]
18. Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules. Berke Z; Andersen MH; Pedersen M; Fugger L; Zeuthen J; Haurum JS Leukemia; 2000 Mar; 14(3):419-26. PubMed ID: 10720136 [TBL] [Abstract][Full Text] [Related]
19. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. Gannagé M; Abel M; Michallet AS; Delluc S; Lambert M; Giraudier S; Kratzer R; Niedermann G; Saveanu L; Guilhot F; Camoin L; Varet B; Buzyn A; Caillat-Zucman S J Immunol; 2005 Jun; 174(12):8210-8. PubMed ID: 15944330 [TBL] [Abstract][Full Text] [Related]
20. A novel MHC-associated proteinase 3 peptide isolated from primary chronic myeloid leukaemia cells further supports the significance of this antigen for the immunotherapy of myeloid leukaemias. Knights AJ; Weinzierl AO; Flad T; Guinn BA; Mueller L; Mufti GJ; Stevanovic S; Pawelec G Leukemia; 2006 Jun; 20(6):1067-72. PubMed ID: 16628186 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]